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Compounds of the class of 4-oxo-butenoic acid derivatives
are disclosed along with the surprising use property of these
compounds as a anti-tumor agents in humans against breast
carcinoma, which include: 2-(N'-Fluoren-9-ylidenehydrazino )-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl
ester (OF-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3( 4-methy 1-benzoy 1)-5-oxo-2,5-dihydro-lH-pyrrole-2carboxylic acid methyl ester (lF-07), 4-(4-Methoxyphenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid (3F10), 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )butyric acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5,
6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15),
and 4,4-Dihydroxy-5-( 4-methyl-benzoyl)-2-phenyl-2,4dihydro-pyrazol-3-one (3F-16) as well as some novel
derivatives of these compounds claimed (see Table 2). The
invention also encompasses a class of the compounds with
the novel property of anti-tumor activity against human
breast cancer, which includes the following compounds
4-( 4-Ethoxy-pheny1)-2-(N'-fiuoren-9-ylidene-hydrazino )-2hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-{N'-[1(4-Chloro-phenyl)-ethylidene ]-hydrazino }-4-oxo-4-phenylbut-2-enoic acid methyl ester (OF-20); 2-(N'-Fluoren-9ylidene-hydrazino )-4-oxo-4-phenyl-but-2-enoic acid methyl
ester (lF-04); and 4-Chloro-4-( 4-ethoxy-phenyl)-2(fiuoren-9-ylidene-hydrazono)-but-3-enoic acid methyl
ester (3F-19).

1 Claim, 2 Drawing Sheets
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Kalden, et al (U.S. Pat. No. 5,334,612) discloses compounds said to be useful for treating AIDS including
derivatives of carboxylic acid (column 9, line 31) and
This application is a divisional of Ser. No. 10/164,541
pyrrolidine (column 7, line 24);
filed Jun. 7, 2002, now U.S. Pat. No. 6,602,907, which
claims benefit of Ser. No. 60/296,823 filed on Jun. 8, 2001. 5
Brown (U.S. Pat. No. 6,066,670) describes an anti-viral
admixture containing crotonic acid for treating tumors
FIELD OF THE INVENTION
(see Abstract);
This invention relates to novel 4-oxo-butenoic acid
Harwell, et al (U.S. Pat. No. 5,580,896) discloses many
derivatives and to the use of these compounds and related
4-oxo-2-butenoic acid derivatives (column 13, lines
compounds with novel biological activity in humans as 10
21-59; also in columns 15+, examples 25,26,32,34,40,
therapeutic means for the prevention and treatment of the
43-46,77-79,97,99,103,106,), which are useful for
human breast cancer and claims the benefit of priority of
inhibiting colorectal cancer, i.e., colon cancer
U.S. Provisional Application Serial No. 60/286,823 filed
(Abstract); and,
Jun. 8, 2001.
Giordani,
et al (U.S. Pat. No. 5,580,890) discloses 4-oxo15
2-butenoic acid derivatives said to be useful for treatBACKGROUND OF THE INVENTION
ment of AIDS (column 1, line 8 and column 2, line 61;
Cancer is a global killer of humans with breast cancer
and,
among the leaders of killing humans yearly. Breast cancer is
Yonemeto,
et al (U.S. Pat. No. 6,083,985) recites a
the primary killer of women. One in eight American women
of
anti-tumor or anti-AIDS agents that include
number
will develop breast cancer in her lifetime. In 2001, an 20
butenoic acid derivatives.
estimated 192,700 women in the U.S. will be diagnosed with
The U.S. patent literature has many disclosures of
invasive breast cancer and 42,600 with in situ (tumors
butanoic acid derivatives including:
contained in the milk ducts). An estimated 40,000 will die
Nicolai, et al (U.S. Pat. No. 6,180,651) discloses many
from the disease.
anti-inflammatory and analgesic compounds, including
An estimated 3 million women in the U.S. today are living 25
adenocarcinoma (column 1, line 55), which includes
with breast cancer of which 2 million have been diagnosed
heterocyclic alcohol-esters (column 11, lines 1-16) and
with the disease and 1 million have the disease but do not yet
butanoic acid derivatives (many Examples including 47
know it.
through 162);
The incidence of breast cancer in the U.S. has more than
Girard, et al (U.S. Pat. No. 5,308,852) discloses many
doubled in the past 30 years. In 1964, the lifetime risk was 30
compounds including butanoic acid derivatives (see
1 in 20. Today it's 1 in 8. Breast cancer is the most
Methods B and C of schemes II and III) which comcommonly diagnosed cancer in women in both America and
pounds which are said to inhibit tumor metastasis
worldwide. Breast cancer rates are the highest in industri(column 7, line 56 and column 8, line 4); and,
alized countries. It is estimated that 1.2 million new diagnoses and 500,000 deaths from breast cancer will occur 35
Frechette (U.S. Pat. No. 5,696,117), Frechette (U.S. Pat.
worldwide this year. Further, it appears that breast cancer is
No. 5,854,242) and Frechette (U.S. Pat. No. 5,707,990)
the leading cause of death for American women of ages 25
describe 148 benzoxazine and pyrido-oxazine heteroto 55 years.
cyclics as anti-bacterial compounds.
It appears from the foregoing that the derivatives of
No vaccine or other universally successful method for the
40
4-oxo-butanoic acid of interest are not disclosed and thus
prevention or treatment of breast cancer is currently availthere is no report of their activity against human breast
able. Management of the disease currently relies on a
cancer.
combination of early diagnosis (through routine breast
Consequently, there is a need for an anti-cancer drug for
screening procedures) and aggressive treatment, which may
humans that mitigates the above mentioned disadvantages of
include one or more of a variety of treatments such as
45
current drug therapy and effectiveness against human breast
surgery, radiotherapy, chemotherapy and hormone therapy.
cancer.
The course of treatment for a particular breast cancer is often
selected based on a variety of prognostic parameters, includSUMMARY OF THE INVENTION
ing an analysis of specific tumor markers. {Porter-Jordan
and Lippman, Breast Cancer 8:73-100 (1994)}. However,
The first objective of the present invention is to provide a
50
the use of established markers often leads to a result that is
drug effective for treatment of human breast cancer.
difficult to interpret, and the high mortality observed in
Another object of this invention is to provide novel
breast cancer patients indicates that improvements are
4-oxo-butenoic acid derivatives.
needed in the treatment, diagnosis and prevention of the
A further object of this invention is to provide 4-oxodisease.
55 butenoic acid derivatives with novel activity against human
Accordingly, there is a need for improved methods for
breast cancer.
chemotherapy for breast cancer. The present invention fulA preferred embodiment of the invention encompasses a
fills this need and further provides other related advantages.
class of compounds having the property of anti-tumor activThe U.S. patent literature has many disclosures of oxoity against human breast cancer comprising the novel strucbutenoic ( crotonic) acid derivatives:
60 tures of 4-oxo-butenoic derivatives and more specifically
Pamukci (U.S. Pat. No. 6,232,312) describes crotonic acid
those derivatives: 2-(N'-Fluoren-9-ylidene-hydrazino)-5,5derivatives (column 22, lines 43-58) for the treatment
dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06),
of colonic polyps;
1-(2,4-Dimethy 1-pheny 1)-2,4-dihydroxy-3-( 4-methy lbenzoyl)-5-oxo-2,5-dihydro-lH-pyrrole-2-carboxylic acid
Jones et al (U.S. Pat. No. 6,121,450) discloses crotonic
acid derivatives (column 8, tine 34; column 78, line 24 65 methyl ester (lF-07), 4-( 4-Methoxy-phenyl)-2,4-dioxo-3and at example 34 as steroid modifiers in treating breast
(phenyl-hydrazono)-butyric acid (3F-10), 4-( 4-Chlorocancer (column 1, lines 55-58);
phenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid ethyl
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ester (3F-11 ), 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafiuoro-4methoxy-phen y l)-but-2-enoic acid (3F-15), and 4,4Dihydroxy-5-( 4-methy l-benzoyl)-2-pheny 1-2,4-dihydropyrazol-3-one (3F-16) as well as novel derivatives of these
compounds (see Table 2).
5
The use of the following compounds for humans as
therapeutic means for the eradication of human breast cancer
further encompasses the following: 4-( 4-Ethoxy-phenyl)-2(N'-fiuoren-9-y lidene-hydrazino )-2-hydroxy-4-oxo-butyric
acid methyl ester (OF-13); 2-{N'-[1-(4-Chloro-phenyl)- 10
ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
methyl ester (OF-20); 2-(N'-Fluoren-9-ylidene-hydrazino)4-oxo-4-phenyl-but-2-enoic acid methyl ester (lF-04); and
4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fiuoren-9-y lidenehydrazono )-but-3-enoic acid methyl ester (3F-19).
15
Further objects and advantages of this invention will be
apparent from the following detailed description of presently
preferred embodiments, which are illustrated structurally in
the accompanying drawings.

To facilitate a full understanding of the invention:
the compound designated as OF-06 is 2-(N'-Fluoren-9y lidene-h ydr azino )-5 ,5-dime thy1-4-o xo-hex -2-e noic
acid methyl ester;
the compound designated as lF-07 is 1-(2,4-Dimethylphenyl)-2,4-dihydroxy-3-( 4-methyl-benzoyl)-5-oxo-2,
5-dihydro-lH-pyrrole-2-carboxylic acid methyl ester;
the compound designated as 3F-10 is 4-(4-Methoxyphenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid
the compound designated as 3F-11 is 4-(4-Chlorophenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid
ethyl ester;
the compound designated as 3F-15 is 2-Hydroxy-4-oxo4-(2,3,5,6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic
acid and,
the compound designated as 3F-16 is 4,4-Dihydroxy-5( 4-methyl-benzoy 1)-2-pheny1-2,4-dihydro-pyrazol-3one.
These compounds have very high activity against human
20
breast cancer and a very low toxicity as Lethal Dose 50
BRIEF DESCRIPTION OF THE FIGURES
(LD 50) in animals. The percent activity and animal toxicity
for each compound is as follows:
FIG. 1 illustrates structurally a chemical compound designated as OF-06.
OF-06 (100% against human breast carcmoma and
LD 50 >3000 mg/kg);
FIG. 2 illustrates structurally a chemical compound des- 25
ignated as lF-07.
lF-07 (100% against human breast carcmoma and
LD 50 >500 mg/kg);
FIG. 3 illustrates structurally a chemical compound designated as 3F-10.
3F-10 (100% against human breast carcinoma and LD 50
<750 mg/kg);
'
FIG. 4 illustrates structurally a chemical compound des30
3F-11 (100% against human breast carcmoma and
ignated as 3F-11.
LD 50 >2000 mg/kg);
FIG. 5 illustrates structurally a chemical compound des3F-15 (100% against human breast carcmoma and
ignated as 3F-15.
LD 50 >200 mg/kg); and,
FIG. 6 illustrates structurally a chemical compound des3F-16 (100% against human breast carcmoma and
35
ignated as 3F-16.
LD 50 >500 mg/kg)
DESCRIPTION OF THE PREFERRED
PREPARATION OF (OF-06)
EMBODIMENTS

EXAMPLE 1
Before explaining the disclosed embodiments of the
present invention in detail, it is to be understood that the 40
The preparation of 2-(N'-Fluoren-9-ylidene-hydrazino)-5,
invention is not limited in its application to the details of the
5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06). A
particular arrangement shown since the invention is capable
solution of 5.0 g (0.02 moles) of 2-hydroxy-5,5-dimethylof other embodiments. Also, the terminology used herein is
4-oxo-hex-2-enoic acid methyl ester (1) (synthesis was
for the purpose of description and not of limitation.
previously published by E. Royals. J. Am. Chem. Soc., 1945,
45
67, 1508) and 3.88 g (0.02 moles) of fiuoren-9-ylideneAs earlier recited this application has been filed in order
hydrazine (2) in 80 mL of absolute toluene was refluxed for
to disclose: new 4-oxo-butenoic acids that have been found
3 hr 30 min with a Dean-Stark trap (control for the end of
to have high activity against human breast cancer and low
the reaction was carried by TLC). The solution was cooled
toxicity in animals.
More specifically this application is for the novel anti- 50 and the precipitate was filtered and recrystallized from
absolute benzene-hexane (1:1) to give 3.4 g (68% yield) of
tumor compounds OF-06, lF-07, 3F-10, 3F-11, 3F-15 and
yellow crystals, mp 135-137° C.
3F-16 which have been structurally shown in FIGS. 1-6,
Solubility: highly soluble in DMSO, DMFA,
respectively, as well as novel derivatives of these comdichloroethane, acetonitrile, slightly soluble in ethanol,
pounds claimed (see Table2) and the activity against human
breast cancer of compounds OF-13, OF-20, lF-04, and 55 tetrachloromethane, insoluble in hexane and water.
3F-19 also as shown in Table 1 along with anti-tumor
The synthesis of OF-06 is an example of well known
activity and toxicity.
amination/dehydration reactions.

OF-06
CH3

I
I
CH3

CH3-C-CO-CH=C-COOCH3

I
OH

+
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CH3
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I

CH3-C-CO-CH2-C-COOCH3

II
I
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CH3

cPo
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N

~

lJLlJ
B

PREPARATION OF (lF-07)

25

EXAMPLE 2

30

-continued

':::~;):,(

<rcn,

The preparation of 1-(2,4-Dimethyl-phenyl)-2,4dihydroxy-3-( 4-methyl-benzoyl)-5-oxo-2,5-dihydro-lH- 35
pyrrole-2-carboxylic acid methyl ester (lF-07). To a solution
CH3
of 1.65 g (0.0051 moles) of 2-(2,4-dimethyl-phenylamino)lF-7
4-oxo-4-p-tolyl-but-2-enoic acid methyl ester (1) in 20 mL
of anhydrous chloroform was added 0.68 g (0.0054 moles)
40
oxalyl chloride. After refluxing for 30 min, 10 mL of
PREPARATION OF (3F-10)
anhydrous hexane was added and 15 ml of solvent was
distilled out. The remainder of the solvent was evaporated
EXAMPLE 3
by keeping the flask open for 12 hr. The resulting precipitate
was filtered and recrystallized from dichloroethane- 45
The preparation of 4-( 4-Methoxy-phenyl)-2,4-dioxo-3tetrachlorometane (1:2) to give 1.25 g (62%) of compound
(phenyl-hydrazono)-butyric acid (3F-10). To a hot stirred
lF-7 in the form of white crystals, mp 133-135° C.
solution of 0.075 moles of 2-Hydroxy-4-( 4-methoxy(decamp.)
phenyl)-4-oxo-but-2-enoic acid in 300 ml of dioxane small
potions of an aqueous solution prepared from 0.075 moles of
50
aniline, 0.92 moles of sodium nitrate and 19 ml of concentrated
HCl in 90 ml of water (DI) was added. During cooling
Solubility: highly soluble in DMSO, acetonitrile, slightly
11.4 g of sodium acetate was added and the reaction was
soluble in dichloroethane, benzene, insoluble in hexane
kept at the r.t. for 24 hr. Then 2 L of water was added to the
tetrachloromethane and water.
55 reaction mixture and the resulting precipitate was filtrated
and recrystallized from 1: 1 mixture of dimethyl chloride/
1. (COCl)2, t
ethyl acetate to give 15.93 g of yellow crystals (60% yield)
2.H20
with m.p. of 176-177 (decamp).

H3C~COOCH3

n,c'Q
0

NH

60

Solubility: highly soluble in DMSO, DMFA, slightly
soluble in chloroform, dichloroethane, insoluble in hexanes.

H3Co-O-co-cH=1-cooH

65
CH3

OH

+
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-continued

-continued
F

[C6HsN2]+c1- -

F

2

H3c o - O - c o - I T - c o - c o o H

5

H 3 C O * ; j CO-CH=1-cooH
OH

N-NHC6Hs

F

3F-10

F
3F-15

10

PREPARATION OF (3F-11)

PREPARATION OF (3F-16)

EXAMPLE 4
The preparation of 4-( 4-Chloro-phenyl)-2,4-dioxo-3(phenyl-hydrazono )-butyric acid ethyl ester (3F-11). A solution of 0.5 g (0.0016 moles) of 5-(4-Chloro-benzoyl)-2phenyl-2H-pyrazole-3,4-dione (1) (synthesis was previously
published by Pimenova, E. V.; Andreichikov, Yu. S. (1992)
Zh. Org. Khim. 28, 376-89) in 2 mL of anhydrous ethanol
was refluxed for 1 hr. The resulting solution was cooled and
the precipitate was filtered to give 0.48 g (85% yield) of
yellow crystals with m.p. of 141-142° C. (decamp).

15

EXAMPLE 7

The preparation of 4,4-Dihydroxy-5-(4-methyl-benzoyl)2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16). A solution of
0.5 g (0.0017 moles) of 5-(4-Methyl-benzoyl)-2-phenyl-2Hpyrazole-3,4-dione (1) (synthesis was previously published
20
by Pimenova, E. V.; Andreichikov, Yu. S. (1992) Zh. Org.
Khim. 28, 376-89) and 5 mL of water (DI) was kept at the
rt until the solution became colorless and precipitate was
formed. The precipitate was filtered and recrystallized from
25 dichloromethane-water (10:1) to give 0.45 g (85%) of
yellow-brown crystals, mp 134-135° C.

40

3F-16

PREPARATION OF (3F-15)
EXAMPLE 6
Solubility: highly soluble in DMSO, dioxane, insoluble in
water.
The preparation of 2-Hydroxy-4-oxo-4-(2,3,5,645
tetrafluoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15). A
solution of sodium methoxide was prepared from 0.46 g (20
PREPARATION OF (OF-13)
mmol) of sodium and 30 mL of absolute methanol by adding
small portions to a mixture of 6.35 g (10 mmol) of
EXAMPLE 8
1-pentafluorophenyl-ethanone 1 and 3.54 g (10 mmol) of
50
dimethyl oxalate 2. After stirring the reaction for 24 hr at rt,
The preparation of 4-( 4-Ethoxyphenyl)-2-(N'-fluoren-950 mL of 25% aqueous solution of HCl was added. The
ylidene-hydrazino )-2-hydroxy-4-oxobutyric acid methyl
resulting mixture was extracted with ether (240 mL),
ester (OF-13). A solution of 5.0 g (0.02 moles) of methyl
washed by solution of brine and dried over anhydrous
4-p-ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and
Na 2 S0 4 . The solvent was removed in vacuum and 10 mL of
55 3.88 g (0.02 moles) of fluorene-9-ylidene-hydrazine (2) in
saturated solution of NaOH in ethanol was added with
80 mL of absolute benzene and absolute toluene (1:1) was
stirring. After 1 hr the reaction mixture was diluted with
refluxed for 1 hr 30 min with a Dean-Stark trap (the end of
water and acidified with H 2 S0 4 (10%) to obtain pH of 1-2.
the reaction was determined by TLC), cooled and the
The resulting precipitate of 3F-15 was filtered and recrysprecipitate was filtered and recrystallized from benzenetallized from toluene to give 1.73 g (81 % yield) in the form
60 diethyl ether-hexane mixture (1:3:2) to give 2.65 g (53%
of white-yellow crystals, mp 155-156° C. (decamp.).
yield) of colorless crystals with mp 114-116° C.
C6Fs-CO-CH3 + (COOCH3)2
1
2

2)HC1
3) NaOH/C2HsOH
65

Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile, insoluble in hexane. The compound is not stable in solutions and decomposes quickly
when the solution is heated or stored for a long time with the
formation of OF-12.

US 6,638,975 Bl
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9
~COOCH3
C2H50~
0

'I

+

OH

1

2

OH

~COOCH3

I

C2H50~
0

NH

~

U------l)
OF-13

OF-12

It is seen from the above that (OF-13) is an intermediate
product during the synthesis of (OF-12).

methyl ester (OF-12) (synthesis was previously published by
Konyukhova, N. A.; Krasnykh, 0. P.; Aliev, Z. G.;
Maslivets, A. N. Cehmistry ofHetorcyclic Compounds (New
PREPARATION OF (3F-19)
York, N.Y., United States) (Translation of Khimiya
Geterotsiklicheskikh Soedineii) (2001), 37(6), 779-780) in
EXAMPLE 9
5 mL of anhydrous benzene 0.3935 g (0.0031 moles) oxalyl
The preparation of 4 Chloro 4 (4 ethoxy phenyl) 2 (fiuoren 45 chloride was added. The reaction mixture was refluxed for 1
hour 40 min, cooled, precipitate was filtered and recrystal9 ylidene hydrazono) but 3 enoic acid methyl ester (3f-19)
to the solution of 10 g (0.0026 moles of 4 (4 Ethoxy phenyl)
lized from absolute benzene to give 0.62 g (54%) of yellow
2 (N' fiuoren 9 yliden hydrazine) 4-oxo-but-2-enoic acide
crystals, m.p. 163-163 (decom).
40

OF-12

US 6,638,975 Bl
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12
-continued

HsC20--0-1=cH-IT-coocH3
Cl

/N

~

lJ-----lJ
3F-19

TABLE 1
Some Compounds of the Invention

#
OF-13

Name

Structure

OH

C2HsO~COOMe

LDsa,
mg/kg Reference

100%

>1500 Miles et. al. UCF-303A

2-{N'-[1-( 4-Chlorophenyl)-ethylidene ]hydrazino }-4-oxo-4phenyl-but-2-enoic acid
methyl ester

83%

>250 Miles et. al. UCF-311C

2-(N'-Fluoren-9-ylidenehydrazino)-4-oxo-4phenyl-but-2-enoic acid
methyl ester

93%

>1000 Andrejchikov, Yurij S.;
Maslivets, Andrej N.;
Krasnykh, Olga P.;
Aleksandrova, Galina A.;
Vozhakova, Alla V Russ.
(1993), CODEN: RUXXE7
RU 2003655 Cl 19931130
Application: RU 915013322 19910704.

4-Chloro-4-( 4-ethoxyphenyl)-2-(fluoren-9ylidene-hydrazono)-but3-enoic acid methyl ester

100%

>200 Konyukhova, N. A.;
Krasnykh, 0. P.; Aliev,
Z. G.; Maslivets, A. N.
Chemistry of Heterocyclic
Compounds (New York,
NY, United States)
(Translation of Khimi ya
Getero-tsiklicheskikh
Soedinenii) (2001), 37(6),
779-780.

ester

NH....._

0

4-( 4-Ethoxy-phenyl)2-(N'-fluoren-9-ylidenehydrazino)-2-hydroxy-4oxo-butyric acid methyl

Activity
(ATCC HIB123)

N

~

V----V
OF-20
0

OCH3

ffrn,
0

/NH

N

Cl
lF-04
0

OCH3
0

/NH

N

oQ)
#

3F-19

C2HsO
0

Cl

/N

oQ)

US 6,638,975 Bl
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TABLE 2
Derivatives of 3F-10 having potential anti-tumor activity

#

Name

Structure

3-[ (4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-phenyl-butyric acid methyl ester

0

N....._

Q
Cl

2

3-[ (4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-p-tolyl-butyric acid methyl ester

0

I
N....._

Q
Cl

2,4-Dioxo-4-p-tolyl-3-(p-tolyl-hydrazono)-butyric acid methyl ester

3

0

I
N
'NH

¢
4

3-[ (4-Chloro-phenyl)-hydrazono ]-4-( 4-methoxy-phenyl)-2,4-dioxo-butyric acid methyl ester

0

I
N
'NH

¢
Cl
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TABLE 2-continued
Derivatives of 3F-10 having potential anti-tumor activity

#

Name

Structure

5

4-(4-Chloro-phenyl)-2,4-dioxo-3-(p-tolyl-hydrazono )-butyric acid methyl ester

0

I
N
Cl

'NH

¢
OCH3

0

I

N-.....
Cl

4-(4-Chloro-phenyl)-3-[(4-methoxy-phenyl)-hydrazono ]-2,4-dioxo-butyric acid methyl ester

NH

¢
4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid ethyl ester

7

0

I

N-.....
Cl

NH

6
8

2,4-Dioxo-3-(phenyl-hydrazono)-4-p-tolyl-butyric acid ethyl ester
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TABLE 2-continued
Derivatives of 3F-10 having potential anti-tumor activity

#

Name

Structure

2,4-Dioxo-4-phenyl-3-(phenyl-hydrazono)-butyric acid methyl ester

9

0

I
N
'NH

6

10

2,4-Dioxo-3-(phenyl-hydrazono)-4-p-tolyl-butyric acid methyl ester

0

I
N......_
NH

6

11

0

I
N......_
Br

12

4-(4-Bromo-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid methyl ester

0

4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester

0

I
N......_
NH

13

6

OCH3

0

I
N......_
NH

6

4-(4-Ethoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester

US 6,638,975 Bl

19

20
TABLE 2-continued
Derivatives of 3F-10 having potential anti-tumor activity

#

Structure

Name

14

4-(4-Fluoro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester

0

I
N
'NH

F

6

15

4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester

Cl

16

3-[ (4-Methoxy-phenyl)-hydrazono ]-2,4-dioxo-4-phenyl-butyric acid methyl ester

0

I
N
'NH

¢
OCH3

17

3-[ (4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-phenyl-butyric acid methyl ester

0

I
N'-.

NH

¢
Cl

CYTOTOXICITY ASSAY
The activity in human breast cancer of the novel compounds (as earlier reported) was realized by the following
procedure which determines the inhibitory effect of test
samples on the growth of human breast cancer cells.
(ATCC HTB123) The HTB123 cells are grown in RPMI
1640 media+10% Fetal bovine serum+4.5 g/L glucose+lO
mM HEPES+ 1.0 mM sodium pyruvate+ 1% Antibiotic/

60

65

Antimycotic for approximately 48 hours at 37° C./5% C0 2
in the presence of the test compound.
Growth/Non-Growth of the cells (e.g., cell density) is
determined using Promega's MTS/PMS assay system. MTS
(3-( 4,5-dime thylthiazo l-2-yl)-5-(3carboxymethoxypheny1)-2-(4-sulfopheny l)-2H-tetrazolium,
inner salt) is an aqueous compound that is reduced to soluble
formazan by the presence of NADH formed by dehydroge-
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nases present within the HTB123 cells. The absorbance of
the formazan can be measured at 490 nm and is directly
proportional to the number of living cells present in the
culture. PMS (Phenazine Methosulfate) is added an electron
coupling reagent and greatly increases the rate of reduction.
To facilitate a full understanding of the procedure the
following definitions are offered:
Test wells-wells containing test sample and Diluted
HTB123 cells
Test values-absorbance of test wells
Blank wells-wells containing test sample and HTB123
media (HHTB2-01S); used to obtain background
absorbance due to test sample
Blank values-absorbance of blank wells
Negative Control-maximal cell growth; results of test
samples will be expressed as a percent of the Negative
Control
Positive Control-known inhibitor of HTB123 cells; used
to validate assay system
Matrix-solvent that the samples are prepared/diluted in
Assay samples of similar origin and matrix (e.g., methanol extraction, methylene chloride extraction, water soluble
samples, etc.) together on the same plate in order to reduce
the number of steps performed per plate.
Blank values will be determined for each sample to
account for any color contribution due to the sample itself.
These blank wells must contain the same amount of sample
plus HTB123 media (no cells). After completion of MTS/
PMS reaction blank values will be subtracted from the test
value to obtain a net absorbance that will be used to calculate
cell density.
All results are based upon a comparison to the Negative
Control value of the plate. The Negative Control must
contain the same amount of matrix (e.g., solvent) to offset
any destructive effect the matrix may have on the growth of
the HTB123 cells (allows for baseline values to be set).
For most samples, a HTB123 cell growth (diluted two to
four-fold, depending upon the appearance of the inoculum*)
of approximately 48 hours followed by and incubation of 3
hours with the MTS/PMS Reagent is optimal.

tives: 2-(N'-Fluoren-9-ylidene-hydrazino)-5,5-dimethyl-4oxo-hex-2-enoic acid methyl ester (OF-06), 1-(2,4Dimethy1-pheny1)-2,4-dihydroxy-3-(4-meth y1-benzoy1)-5oxo-2,5-dihydro- lH-pyrrole-2-carboxy lic acid methyl ester
(lF-07); 4-( 4-Methoxy-phenyl)-2,4-dioxo-3-(phenylhydrazono )-butyric acid (3F-10), 4-( 4-Chloro-phenyl)-2,4dioxo-3-(phenyl-hydrazono )-butyric acid ethyl ester (3F11); 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafiuoro-4-methoxyphenyl)-but-2-enoic acid (3F-15) and, 4,4-Dihydroxy-5-(4methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3F16), as well as all novel derivatives of these compounds
claimed (see Table2), and the additional compounds of Table
1 with activity against human breast cancer which includes
the following compounds 4-( 4-Ethoxy-phenyl)-2-(N'fiuoren-9-ylidene-hydrazino )-2-hydroxy-4-oxo-butyric acid
methyl ester (OF-13); 2-{N'-[1-(4-Chloro-phenyl)ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
methyl ester (OF-20); 2-(N'-Fluoren-9-ylidene-hydrazino)4-oxo-4-phenyl-but-2-enoic acid methyl ester (lF-04); and
4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fiuoren-9-y lidenehydrazono)-but-3-enoic acid methyl ester (3F-19).
All the compounds are unique in the in vitro treatment of
humans and can be used as therapeutic means for the
eradication of tumors from the human breast in a pharmaceutical composition comprising a non-toxic effective
amount of the referenced compound or a tautomeric form
thereof or a pharmaceutically acceptable salt thereof or
pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier thereof.
For administration to man in the curative or prophylactic
treatment of human breast cancer in vitro dosages of compounds of the invention will generally be in the range of
from 5 to 500 mg daily for an average adult patient (70 kg).
Thus for a typical adult patient, individual tablets or capsules
contain from 2-500 mg of active compound, in a suitable
pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per
day. Dosages for intraveneous, buccal or sublingual administration will typically be within the range of from 5-1000
mg per single dose as required. In practice the physician will
determine the actual dosing regimen which will be most
suitable for an individual patient and it will vary with the
age, weight and response of the particular patient. The above
dosages are exemplary of the average case but there can be
individual instances in which higher or lower dosage ranges
may be merited, and such are within the scope of this
invention.
The maximum human non-toxic one time administration
dose for the compound(s) of the invention appears to range
from 100 to 1500 mg.
For human use, the compounds of the invention can be
administered alone or jointly, but will generally be administered in admixture with a pharmaceutical carrier selected
with regard to the intended route of administration and
standard pharmaceutical practice. For example, they may be
administered orally, buccally or sublingually, in the form of
tablets containing excipients such as starch or lactose, or in
capasules or ovules either alone or in admixture with
excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. The compounds may also
be injected parenterally, for example intraveneously,
intramuscularly, subcutaneously or intracoronarily. For
parenteral administration, they are best used in the form of
a sterile aqueous solution which may contain other
substances, for example enough salts or glucose to make the
solution isotonic with blood.
The invention thus provides a method for the treatment of
breast carcinoma in a human mammal which comprises
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*Due to the nature of the HrB123 cells it is very difficult to obtain accurate 40
cell densities. Continuation of the HrB123 cell line typically consists of the
dilution of mature cells at two or three-fold into fresh media and growth at
37° C./5% C0 2 for two to three days.

In order to establish the accuracy of this assay a Positive
Control consisting of 50 µM Methotrexate should not
decrease the net absorbance to less than 90% of the Negative
Control (HTB123 cells are somewhat resistant to methotrexate) is utilized.
ANIMAL TOXICITY BIOASSAY
Acute toxicity was studied on white mice of both sexes
with weight ranging between 18-26 grams under intraperitoneal injection of 2% solution of tested compound in starch
(the compound was dissolved in starch slime and injected)
on the basis of 0.1 ml of solution per 10 g of the animal
weight. Each dose was tested on the group of 6 animals that
were observed during 14 days period. (This method was
approved by the Pharmacology committee of Russian Ministry of Health and has been widely used since 1968.)
Averaged lethal dose (LD 50 ) of the compound was computed using results of experiments on 5-7 groups of animals
using method of Litchfield and Wilkinson. (Belenkii M. L.
"Elements of quantative determination of the pharmacological effect," Leningrad, 1963, 71 pages).
USE OF THE INVENTION FOR TREATMENT
OF HUMAN BREAST CANCER
The compounds of the invention, i.e. 4-oxo-butenoic
acids derivatives and more specifically those novel deriva-
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administering an effective, non-toxic, amount of a heteroAccordingly, there is a need in the art for improved
cyclic compound according to the invention or a tautomeric
methods for therapy and diagnosis of breast cancer. The
form thereof and/or a pharmaceutically acceptable salt
present invention fulfills these needs and further provides
thereof and/or a pharmaceutically acceptable solvate
other related advantages. The animal toxicity bioassay data
thereof, to a breast carcinoma invaded human mammal in 5 indicated that LD dose for all of the compounds are in the
50
need thereof.
range of 250-3000 mg/kg, which is much lower compare to
some of the most promising agents against breast cancer. For
ADVANTAGES OF THE INVENTION
example taxol intraperitoneal LD 50 dose in mice using the
Breast cancer is a significant health problem for women in
same bioassay system is 218 mg/kg (JZKEDZ 6,1,1980),
the United States and throughout the world. Although
advances have been made in detection and treatment of the 10 which is almost a number of magnitude higher then some of
the claimed compounds. Such a low toxicity dose of the
disease, breast cancer remains the second leading cause of
compounds claimed gives a strong potential for not to
cancer-related deaths in women, affecting more than 180,
having such a serious side effects as the most potential drugs
000 women in the United States each year. For women in
North America, the life-time odds of getting breast cancer
of the present time do. Secondly, more advantages from our
are now one in eight.
15 invention are the cheapness and the simplicity of the synthesis of active compounds compare to the present drugs on
No vaccine or other universally successful method for the
prevention or treatment of breast cancer is currently availthe market. The synthesis of claimed compounds from
able. The available drugs on the market have a variety of
commercially available reagents takes four to five synthetic
strong side effects, high cost and complicated synthesis. For
steps with overall yield in the range of 60--85%. Versus for
example, Taxol is the most promising antitumor agent 20 example taxol which takes minimum of 40 synthetic steps
developed in the past three decades. It was approved by the
with only 2% overall yield, which increases the price of the
FDA for the treatment of refractory ovarian cancer in
compound dramatically.
December, 1992, and was introduced into the marketplace in
Conclusion: Although the invented compounds have not
January, 1993 by Bristol-Myers Squibb Company (EMS)
operating under a Cooperative Research and Development 25 yet been tested clinically, one can see from the Table 1 that
all of them posses at least 10 times lower acute toxicity
Agreement (CRADA) with the National Cancer Institute
compare to the most promising antitumor agent developed in
(NCI). It was approved for the treatment of breast cancer in
the past three decades, high activity values, ease of
1994, and is now in transition from second line to first line
synthesis, and cheap cost. All these advantages provide a
therapy. Worldwide sales of Taxol reached $1.2 billion in
1998. However, Preclinical development continued from 30 potential for the development of new drugs for the prevention or treatment of breast cancer.
1977 until 1983, hampered by a number of obstacles,
especially the formulation problem. Taxol is highly lipoWhile the invention has been described, disclosed, illusphilic and is insoluble in water. Finally, a vehicle consisting
trated and shown in various terms of certain embodiments or
of a mixture of Cremophore EL (polyethoxylated caster oil),
modifications which it has presumed in practice, the scope
ethanol and saline was chosen, but its toxicity was a sig- 35 of the invention is not intended to be, nor should it be
nificant problem in preclinical studies. The main side effects
deemed to be, limited thereby and such other modifications
of this drug were found to be congenital malformation in the
or embodiments as may be suggested by the teachings herein
fetus and reproductive disorders. The supply of Taxol was
are particularly reserved especially as they fall within the
also a problem. To obtain Yew bark, the tree had to be killed.
breadth and scope of the claims here appended.
A large Pacific Yew two feet in diameter requires 200 years 40
We claim:
to grow and yields about five pounds of bark. In extractions
1. A method of treating breast carcinoma in a human in
by Polysciences, then the only extraction contractor, a
need of such treatment comprising the steps of administering
0.004% yield of Taxol was obtained. Furthermore, the
to said human, in a systemic, in vitro manner, an anti-tumor
Pacific Yew was a scarce understory tree, and its extinction
and destruction of the old growth forests was threatened by 45 effective amount of a compound selected from the group
consisting of
the harvest. Few believed, because of the complexity of the
molecule, that the problem of a commercial supply of Taxol
4-(4-Ethoxy-pheny1)-2-(N'-fiuoren-9-ylidene-hydrazino )could be solved by total synthesis. The first total synthesis
2-hydroxy-4-oxo-butyric acid methyl ester;
was finally reported in 1994 by the Holton group. Although
2-{N'-[1-( 4-Chloro-phenyl)-ethylidene ]-hydrazino }-4three total syntheses have been subsequently achieved by 50
oxo-4-phenyl-but-2-enoic acid methyl ester;
others, the Holton synthesis is the most efficient, but still
4-Chloro-4-( 4-e thoxy-pheny 1)-2-( fl uoren -9-y lidenerequires over 40 steps from camphor and provides an overall
hydrazono )-but-3-enoic acid methyl ester; and
yield of approximately 2%.
2-(N'-Fluoren-9-y lidene-hydrazino )-4-oxo-4-pheny l-butTaxol is perhaps best viewed as an exciting and valuable
2-enoic acid methyl ester
lead in cancer chemotherapy. Although Taxol has extended 55
having
the common property of anti-tumor activity against
the life of many people, it is not a cure, and many patients
human breast cancer.
develop resistance to it. Many tumor types show minimal or
no response to Taxol, and there are solubility problems in
drug delivery.
* * * * *

